GILEAD SCIENCES, INC. Cash & Equivalents 2006-2026 | GILD
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is GILEAD SCIENCES, INC.'s current cash & equivalents?
GILEAD SCIENCES, INC. (GILD) annual cash & equivalents for 2025 was $7.56B, a 24.29% decline from 2024. GILEAD SCIENCES, INC. cash & equivalents for the quarter ending March 31, 2026 was $7.63B.
What was GILEAD SCIENCES, INC.'s cash & equivalents in 2024?
GILEAD SCIENCES, INC. annual cash & equivalents for 2024 was $9.99B, a 64.19% increase from 2023.
What was GILEAD SCIENCES, INC.'s cash & equivalents in 2023?
GILEAD SCIENCES, INC. annual cash & equivalents for 2023 was $6.08B, a 12.44% increase from 2022.
What is GILEAD SCIENCES, INC.'s 5-year cash & equivalents CAGR?
GILEAD SCIENCES, INC. cash & equivalents grew at a compound annual growth rate (CAGR) of 4.75% from FY2020 to FY2025, going from $6.00B to $7.56B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $7.56B | -24.3% | 10-K |
| FY2024 | $9.99B | +64.2% | 10-K |
| FY2023 | $6.08B | +12.4% | 10-K |
| FY2022 | $5.41B | +1.4% | 10-K |
| FY2021 | $5.34B | -11.0% | 10-K |
| FY2020 | $6.00B | -48.4% | 10-K |
| FY2019 | $11.63B | -35.2% | 10-K |
| FY2018 | $17.94B | +136.4% | 10-K |
| FY2017 | $7.59B | -7.8% | 10-K |
| FY2016 | $8.23B | -36.0% | 10-K |
| FY2015 | $12.85B | +28.2% | 10-K |
| FY2014 | $10.03B | +374.5% | 10-K |
| FY2013 | $2.11B | +17.1% | 10-K |
| FY2012 | $1.80B | -81.7% | 10-K |
| FY2011 | $9.88B | +988.7% | 10-K |
| FY2010 | $907.9M | -28.7% | 10-K |
| FY2009 | $1.27B | -12.8% | 10-K |
| FY2008 | $1.46B | +50.7% | 10-K |
| FY2007 | $968.1M | +18.6% | 10-K |
| FY2006 | $816.0M | - | 10-K |